Our Company

A patient walks out of her cataract surgery, accompanied by her nurse
  • Our Company

We are reimagining medicine

At Novartis, we use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

The Novartis Mission and Vision

Our mission is to discover new ways to improve and extend people`s lives.

Our vision is to be a trusted leader in changing the practice of medicine.

Our Business

Novartis is structured to deliver innovative products, exploit global scale, and respond to new opportunities and risks. Our businesses - Innovative Medicines, Alcon and Sandoz - are supported by functional organizations with global scale. Research and development (R&D) is at the core of our company and central to the Novartis strategy.

  • Innovative Medicines

    Made up of two business units – Pharmaceuticals and Oncology – our Innovative Medicines Division aims to bring more medicines to more patients more efficiently than any other drug development organization in the world.

  • Alcon

    Alcon provides innovative products that enhance quality of life by helping people worldwide see better.

  • Sandoz

    Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines.

  • The Novartis Institutes for BioMedical Research (NIBR)

    NIBR is the innovation engine of Novartis. We collaborate across scientific and organizational boundaries.

Novartis Global Product Portfolio and Clinical Pipeline
Novartis Corporate History

Novartis was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products.

Awards and Recognition

Novartis is honored to receive numerous awards for progress in research and development, our working environment, and our corporate responsibility activities.

  • Fortune Magazine Award

    Fortune’s Change the World list 2017

    Novartis ranked #4 in Fortune’s list of companies that are doing well by doing good.